To evaluate the long-term predictability, stability, safety, and efficacy of the V4c Visian implantable collamer lens (ICL) with central hole to correct myopia. Patients and methods: One hundred and eighty-four eyes of 92 patients were evaluated during 3 years after implantation of the V4c ICL. The refraction, uncorrected distance visual acuity, best-corrected distance visual acuity, IOP, endothelial cell count, vault, and adverse effects were evaluated every 12 months during the whole follow-up. Results: The mean spherical equivalent dropped from -8.30±2.98 D preoperatively to -0.37±0.47 D at 36 months post-surgery, with 91.8% eyes being within ±1.00 D of emmetropia. With respect to the astigmatic components J0 and J45, 98.4% and 99.5% of eyes, respectively, were within ±0.50 D of the desired refraction. At 36 months, 78.8% of eyes had no change in the Snellen lines of best-corrected distance visual acuity, while 8.7% gained one line and 6.5% gained two or more lines; mean safety and efficacy indexes were 1.03 and 0.90, respectively. Mean endothelial cell count was 2,742±340 cells/mm 2 before and 2,663±366 cells/mm 2 at 36 months post-surgery. Mean IOP reduced from 13.7±1.9 mmHg preoperatively to 12.8±1.7 mmHg at 36 months post-surgery. Mean vault varied from 409±196 µm at 12 months to 349±165 µm at 36 months.
Introduction
Phakic intraocular lens (pIOL) implantation is a precise and a reproducible technique that is widely used in patients with moderate to high ametropias who do not wish to have a corneal refractive procedure or have a contraindication for corneal refractive surgery. 1, 2 The Visian implantable collamer lens (ICL) (Staar Surgical AG, Nidau, Switzerland), which is a posterior chamber pIOL for the treatment of myopia, hyperopia, and astigmatism, has shown excellent outcomes of visual quality, stability, safety, predictability, and effectiveness to correct moderate to severe ametropias. [3] [4] [5] [6] [7] [8] [9] [10] [11] Nevertheless, several complications after ICL implantation have also been reported. 12 These complications include increased IOP, 13 which is usually associated with acute pupillary block 14 or with chronic pigment dispersion, and could be related to inadequate preoperative or intraoperative iridectomies. In addition, anterior subcapsular cataract [15] [16] [17] [18] [19] could appear as a result of ICL and crystalline lens contact because of an insufficient vault (central separation between the ICL and the crystalline lens) or due 
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Fernández-Vega-Cueto et al to a poor circulation of the aqueous humor induced by ICL implantation. 20 The improved model V4c Visian ICL has been designed with a central hole of 0.36 mm (the KS-Aquaport) to overcome these disadvantages, allowing a more natural flow of the aqueous humor. With the central KS-Aquaport, the need to perform preoperative Nd:YAG peripheral iridotomies or intraoperative iridectomies is eliminated, reducing the overall procedure time and enhancing patients' comfort. The improvement of aqueous humor circulation reduces the incidence of cataracts. 21, 22 Some previous studies have shown that the ICL with central hole has no optical effect on vision; [21] [22] [23] [24] [25] [26] only one study related the possibility of ringshaped dysphotopsia after hole ICL implantation due to light refraction at the central hole structure. 27 Simulation analyses and studies performed in porcine eyes have shown that the central hole increases the aqueous humor perfusion volume on the anterior surface of the crystalline lens, preventing the formation of lens opacities. 28, 29 The aim of this retrospective study was to assess the longterm clinical and refractive outcomes of the V4c Visian ICL with central hole model to correct moderate to high myopia over a 36-month period.
Patients and methods
This retrospective study included 184 eyes of 92 patients (30 male, 62 female) who had implantation of a V4c ICL model to correct myopia. Table 1 shows the preoperative patients' demographics and pIOL characteristics. All patients provided written informed consent after the nature and the possible consequences of the study, approved by the Fernández-Vega Ophthalmological Institute Board, were explained to them fully in accordance with the Declaration of Helsinki.
The inclusion criteria were best-corrected distance visual acuity (CDVA) of 20/40 or better, stable refraction for 2 years, and clear central cornea. The exclusion criteria were age ,20 years, anterior chamber depth ,2.8 mm, endothelial cell count (ECC) ,2,000 cells/mm 2 , cataract, history of glaucoma or retinal detachment, macular degeneration or retinopathy, neuro-ophthalmic diseases, and history of ocular inflammation.
Before surgery, all patients had a complete ophthalmologic examination. The evaluation included manifest and cycloplegic refractions, keratometry, corneal topography, ECC, pachymetry (Orbscan II; Bausch & Lomb, Rochester, NY, USA), slit-lamp microscopy, Goldmann applanation tonometry, and binocular indirect ophthalmoscopy through a dilated pupil. The target was emmetropia in all cases.
piOl size and power calculation
The V4c Visian ICL with central hole is a phakic lens made from collamer (Staar Surgical AG proprietary), a flexible, hydrophilic, and biocompatible material with a plate-haptic design and a central convex/concave optical zone. The ICLs are foldable, allowing for posterior chamber injection through a microscopic incision of 3.5 mm or smaller. When properly placed, the ICL should be positioned completely within the posterior chamber between the iris and crystalline lens with support on the ciliary sulcus. In the present study, we analyzed the V4c ICL model, which introduces a central hole to avoid the peripheral iridectomies and increase the aqueous humor perfusion, thereby reducing the risk of secondary cataract formation. 21, 22 pIOL power calculation is performed using the software provide by the manufacturer. White-to-white and anterior chamber depth distances were measured in order to determine the appropriate size of the ICL. The mean optical power of the V4c ICL implanted in the sample of the study was -9.11±2.83 D, range (-18.0, -3.5), and the lens sizes chosen for all patients were 12.6, 13.2, or 13.7 mm. 
surgical technique
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V4c iCl 3-year follow-up minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks. The second eye had surgery during the first postoperative week of the first eye. All eyes were targeted for emmetropia. Figure 1 shows an example of a lens implanted in one of the patients included in this study.
Follow-up
Follow-up visits were done at 1 day, 1 week, and 1, 3, 12, 24, and 36 months, although this manuscript reports results obtained at long term in 12, 24, and 36 months of follow-up. The examinations included uncorrected distance visual acuity (UDVA), CDVA, refractive status, slit-lamp examination, tonometry, ECC, and vault measured by the anterior segment optical coherence tomographer Visante. The vault between the crystalline lens and the ICL was measured perpendicular to the lens apex or at the narrowest space between both. During the follow-up period after surgery, two patients had to undergo ICL rotation after implantation due to high vault (greater than 1,200 µm). Two patients underwent postoperative refraction correction by means of LASIK with optimized excimer laser at 24 and 36 months, respectively. No additional intraoperative complications were reported in other patients and there were no cases of pIOL decentration. Assessment of outcomes was based on preoperative vs postoperative CDVA and UDVA values (efficacy and safety indexes), the achieved vs the expected postoperative refractive outcomes (predictability), and the refractive outcomes variability during the postoperative follow-up period (stability). The efficacy index (defined as the ratio between the postoperative UDVA and the preoperative CDVA) and the safety index (defined as the ratio between the postoperative CDVA and the preoperative CDVA) were also calculated based on Snellen decimal visual acuity values. Manifest refractions were recorded in conventional script notation (sphere S, cylinder C, axis α) and then converted to power vector coordinates by the following formulas:
where M is equal to the spherical equivalent (SE) of the given refractive error, J0 is the Jackson cross-cylinder with axes at 180° and 90°, and J45 is the Jackson cross-cylinder with axes at 45° and 135°.
statistical analysis
Data analysis was performed using Excel (version 2016; Microsoft Corporation, Redmond, WA, USA) and statistical analysis was performed using SPSS statistical software (version 24.0; IBM Corp., Armonk, NY, USA). A repeatedmeasure ANOVA (rANOVA) was performed to reveal significant differences through the follow-up period. The normality of all data sets was evaluated by means of the Shapiro-Wilk test. The ANOVA procedure based on the F statistic is robust under the breach of the normality assumption, provided that the data samples have no important asymmetries or similar distribution shapes. 31 Prior to the rANOVA, the sphericity assumption was checked using the Mauchly's sphericity test. In cases in which sphericity could not be assumed, the Greenhouse-Geisser correction was applied. 32 The Bonferroni procedure was used as a post hoc test for comparisons between data groups when the rANOVA revealed significant differences between measurements. This method allows for obtaining the significance level for paired differences between the individual conditions. The statistical significance limit was set to P,0.05 in all cases. With respect to the astigmatic components J0 and J45, Figure 3 shows the preoperative and 12, 24, and 36 months postoperative astigmatic components of the power vector represented by the two-dimensional vector (J0, J45). As can be seen in the figure, during the whole postoperative follow-up, the distribution of points is tighter around zero compared to Figure 4 . The change in SE from preoperative to 12, 24, and 36 months after surgery was statistically significant (P,0.001).
Results Predictability
safety Figure 5 shows the safety results at 12, 24, and 36 months postoperatively. At the end of the follow-up, 5.98% (11 eyes) had lost one line of CDVA, 78.8% (145 eyes) had no change from preoperatively, 8.7% (16 eyes) had gained one line of CDVA, 4.89% (9 eyes) had gained two lines, and 1.63% (3 eyes) had gained three or more lines. The mean safety index was 1.04, 1.03, and 1.03 for 12, 24, and 36 months postoperatively, respectively. Figure 6 shows the cumulative proportion of eyes having a given UDVA value at 12, 24, and 36 months postoperatively. The UDVA was 20/20 or better in 98 eyes (56.0%, 175 eyes measured) and 20/25 or better in 132 eyes (75.4%) at 3 years of follow-up, while preoperatively, all eyes had an UDVA worse than 20/63. Figure 7 shows the cumulative proportion of eyes having a given CDVA value, both preoperatively and at 12, 24, and 36 months postoperatively. The preoperative CDVA was 20/20 or better in 147 eyes (79.9%) and 20/25 or better in 168 eyes (91.3%), while the postoperative values at 36 months of follow-up increased to 161 eyes (87.5%) and 175 eyes (95.1%), respectively. The mean efficacy index was 0.99, 0.92, and 0.90 for 12, 24, and 36 months postoperatively, respectively. intraocular pressure Figure 8 shows the evolution in the mean IOP for the whole follow-up period. The mean IOP had a significant small reduction from preoperatively to 12 months post-surgery 
Efficacy
endothelial cell count
The mean preoperative ECC was 2,742±340 cells/mm 2 (179 eyes measured), while the values obtained at 12, 24, and 36 months post-surgery were 2,726±380, 2,720±404, and 2,663±366 cells/mm 2 , respectively (184 eyes in all cases). Figure 9 shows the temporal evolution of the mean ECC from the preoperative value to the 36 months post-surgery value. From the statistical point of view, the ECC values remained significantly stable during the whole follow-up period (P=0.080).
Vault
The mean vault between the crystalline lens and the ICL changed significantly from 409±196 µm at 12 months post-surgery to 357±178 µm at 24 months of follow-up (P,0.001). This value was significantly stable (P=0.311) from 24 months post-surgery to the value obtained at 36 months of follow-up (349±165 µm). Figure 10 shows the evolution of mean vault values for the postoperative follow-up period (184 eyes measured in all cases).
Discussion
This retrospective study included 184 eyes of 92 patients who underwent V4c pIOL implantation. Its aim was to evaluate the long-term post-surgery results assessing whether this central hole-based model is safe, effective, and predictable in correcting myopia through 3 years of follow-up.
Several studies have been previously performed to evaluate the long-term refractive and visual stability related to the implantation of previous ICL models (V3, V4, V4 toric). [33] [34] [35] Moya et al 33 evaluated the long-term refractive results after the implantation of V3 and V4 ICL models for myopia, including in the retrospective study 144 eyes with clinical data available 12 years after the implantation. of this long period of follow-up, only 8.9% of eyes had lost more than two lines of CDVA. The incidence of clinically relevant cataracts (13.9%) was significantly linked to the use of the V3 model. Also, they concluded that these ICL models provided good refractive outcomes and stability in the long term. In the study reported by Lee et al, 34 the development of lens opacity and posterior phacoemulsification. According to the authors, the rates of cataract formation at 10 years have important clinical implications, and as such, this information should be part of the available patient information before ICL implantation. Finally, the mean IOP was 15 mmHg immediately postoperatively, and there was no significant increase observed during the 10 years of follow-up. With the results obtained in this retrospective study, the authors concluded that V4 and V4 toric ICL implantation provides good long-term (10-year) safety and stability of refraction in patients with high myopia compared with similar short-term studies.
Regarding the implantation of the V4c model with central hole, most of the comparative studies [21] [22] [23] [24] [25] [26] agreed that the central hole-based ICL appears to be equivalent in the induction of higher-order aberrations, contrast sensitivity function, optical performance including intraocular scattering, UDVA, CDVA, manifest refractive SE, and ECC to previous ICL models for the correction of moderate to high myopia in the short follow-up periods evaluated. Only one study 27 related possible ring-shaped dysphotopsia to hole ICL implantation, associated with light refraction at the central hole structure.
Recently, an additional clinical study has been reported by Shimizu et al 36 to assess the long-term results obtained after the implantation of the V4c ICL model. Examinations were conducted on 64 eyes of 32 consecutive patients in whom implantation of a hole V4c ICL was performed in one eye and that of a conventional ICL was carried out in the other eye by randomized assignment. The mean SE of the patients was -7.53±2.39 D. The follow-up period extended up to 5 years postoperatively, and the safety, efficacy, predictability, stability, IOP, ECC, and adverse events were assessed and compared over this period. The visual acuity results for logMAR UDVA and CDVA at the end of the follow-up were -0.17±0.14 and -0.24±0.08, respectively, in the V4c ICL group and -0.16±0.10 and -0.25±0.08, respectively, in the conventional ICL group. In both groups, and at the end of the follow-up period, 96% and 100% of eyes, respectively, were within ±1.0 D of the targeted correction. Manifest refraction changed by -0.17±0.41 and -0.10±0.26 D from 1 month to 5 years in the V4c and conventional ICL groups, respectively. Only one eye (3.1%), which was in the conventional ICL group, developed an asymptomatic anterior subcapsular cataract. This study concluded that both V4c and conventional ICLs corrected the ametropia successfully throughout the 5-year follow-up period, and demonstrated that the presence of the central hole in the V4c ICL model does not significantly affect visual and refractive outcomes. In our case, we believe that the aqueous humor flow through the hole lifts the lens (forward the lens) and separates it from the ICL. Higher vaults are obtained compared with the previous V4b model using the same lens calculation technique, and taking into account that cataract is produced by the contact of the ICL with the crystalline lens, we expect to have no cataracts.
The present study, in which the number of eyes included in the 3-year long-term follow-up period has been around the triple of that included in the study reported by Shimizu et al, 36 shows comparable results, allowing to conclude that V4c ICL long-term implantation is predictable and stable and is a safe and effective procedure to correct ametropia. As pointed out 
